Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer

Immune checkpoint blockade therapy by targeting the programmed death protein 1/programmed death ligand 1 (PD-L1) axis using antibodies has yielded promising clinical responses in patients with non-small cell lung cancer (NSCLC). However, owing to the dynamic expression of PD-L1, degree of mutational...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoming, Cho, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5250626/
https://www.ncbi.nlm.nih.gov/pubmed/28108884
http://dx.doi.org/10.1186/s40169-017-0136-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5250626/
https://www.ncbi.nlm.nih.gov/pubmed/28108884
http://dx.doi.org/10.1186/s40169-017-0136-7

Ejemplares similares